Pfizer

Activities: Manufacturing Research & Development Pharmaceutical

Trending Articles

  1. Abbott hit with multiple FDA complaints in warning letter The FreeStyle Libre manufacturer has been in the agency's line of fire after it deemed the company's response to previous letters "inadequate"
  2. NHS, MHRA and Medicines UK launch Project Revive to tackle medicine shortages NHS England, the MHRA and Medicines UK have launched Project Revive, a collaborative pilot designed to address critical medicines shortages by fast-tracking dormant...
  3. You need to be a subscriber to read this article.
    Click here to find out more.
    Overcoming the hurdles of strategic market expansion Ramprasad Kaparaboyena, Regulatory Affairs Manager and QP for Pharmacovigilance at Gaelic Laboratories, discusses how to overcome the challenges of expanding your pharma market...
  4. You need to be a subscriber to read this article.
    Click here to find out more.
    Reimagining biosimilars: faster access, stronger supply, sustainable healthcare Outdated development models, uneven adoption and policy barriers are holding Europe back. Dr Kevin Robinson (KSR) spoke to Matt Erick (ME), Head of Advanced Markets at Biocon...
  5. AstraZeneca strengthens weight management pipeline with CSPC Pharmaceuticals collaboration The pair have signed a strategic collaboration covering eight obesity and type 2 diabetes programmes, including a clinical-ready GLP-1/GIP asset, AI-driven peptide discovery...

Upcoming event

High Shear = Mixing Success

19 February 2026 | Virtual See all

Related Content

Regulatory

FDA considers black box warning for COVID-19 vaccines amid internal disputes

The US FDA is reportedly weighing a black box warning for COVID-19 vaccines — a move that has alarmed public health leaders and vaccine manufacturers, who say no new safety signals support such action
Finance

Pfizer completes $10bn acquisition of Metsera to kickstart its GLP-1 goals

The acquisition brings promising clinical-stage obesity candidates into Pfizer's portfolio, giving the pharma company a leg up in one of the most dynamic and high-growth therapeutic areas
Finance

Pfizer clinches $10bn deal to acquire weight-loss biotech Metsera after bidding war with Novo Nordisk

Metsera says that it has opted for Pfizer's revised deal after antitrust concerns surrounding rival Novo's bid for the biotech
Finance

Pfizer denied restraining order on rival Novo Nordisk in GLP-1 bidding war

The Delaware Chancery Judge rejected Pfizer's request for a temporary restraining order, arguing that the company's objections to Novo's proposed deal weren't a legitimate reason for stopping the competitor's offer
Finance

Metsera declares $10bn Novo deal "superior" after Pfizer files second lawsuit in GLP-1 row

Metsera has said Novo Nordisk’s revised offer is a “superior proposal” to Pfizer’s, escalating a high-stakes legal and acquisition battle and where Pfizer has filed a second lawsuit accusing Novo of anticompetitive behaviour and Metsera of collusion
Finance

Pfizer sues Metsera and Novo Nordisk over alleged breach of merger agreement

Pfizer has filed a lawsuit against Metsera, its Board of Directors and Novo Nordisk, alleging breach of contract, fiduciary duty and interference following Metsera’s decision to pursue a rival offer that Pfizer claims is “illegal”
Regulatory

Pfizer strikes landmark deal with US government to lower drug prices

The agreement ensures Americans pay less for medicines while giving Pfizer tariff certainty and a clear pricing framework, enabling $70bn in US investment and a renewed focus on next-generation therapies in cancer, obesity, vaccines and immunology
Subscribe now